Daewoong Co., Ltd

Insider Reports History

Reporting-owner location: Seongnam Si, Gyeonggi Do, Korea, Republic of
Latest reporting-owner signature: Daewoong Co., Ltd., By: /s/ Kyu Sung Lim, Authorized Signatory
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Daewoong Co., Ltd

Form 4 holding 10%+ Owner

AEON Biopharma, Inc.

Security class: Common Stock, $0.0001 par value per share
Shares / value: 11,951,714
Estimated value: $13,152,861
Report date: 21 Jan 2026
Price: $1.10
Ownership: Indirect Beneficial Ownership in the 11,951,714 owned by Daewoong Pharmaceutical Co., Ltd

Form 4 holding 10%+ Owner

AEON Biopharma, Inc.

Security class: Common Stock, $0.0001 par value per share
Shares / value: 58,023
Estimated value: $63,854
Report date: 21 Jan 2026
Price: $1.10
Ownership: Direct

Insider Reports Filed by Daewoong Co., Ltd

3 AEON

AEON Biopharma, Inc.

Report period: 21 Jan 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 29 Jan 2026, 21:25
Role: 10%+ Owner
Next action: Open filing details

4/A AEON

AEON Biopharma, Inc.

Report period: 12 Apr 2024
Transactions: 1
Transaction value: +$10,000,000
Accepted by SEC: 16 Apr 2024, 21:09
Role: 10%+ Owner
Next action: Open filing details

4 AEON

AEON Biopharma, Inc.

Report period: 11 Apr 2024
Transactions: 1
Transaction value: +$10,000,000
Accepted by SEC: 12 Apr 2024, 07:00
Role: 10%+ Owner
Next action: Open filing details

4 AEON

AEON Biopharma, Inc.

Report period: 24 Mar 2024
Transactions: 1
Transaction value: +$5,000,000
Accepted by SEC: 26 Mar 2024, 06:39
Role: 10%+ Owner
Next action: Open filing details

3 AEON

AEON Biopharma, Inc.

Report period: 21 Jul 2023
Transactions: 0
Transaction value: $0
Accepted by SEC: 28 Jul 2023, 07:54
Role: 10%+ Owner
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .